213 related articles for article (PubMed ID: 31980330)
21. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
22. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
24. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
[TBL] [Abstract][Full Text] [Related]
25. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
26. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
27. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, Tolerability, and Compliance of Direct Acting Antivirals in Patients with HIV and Hepatitis C Coinfection: A Real-Life Experience.
Mishra S; Taneja S; De A; Verma N; Premkumar M; Naidu GSRSNK; Sharma A; Duseja A; Dhiman RK; Singh V
AIDS Res Hum Retroviruses; 2023 Sep; 39(9):453-458. PubMed ID: 36511384
[TBL] [Abstract][Full Text] [Related]
29. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
30. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
31. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.
Puhr R; Wright ST; Hoy JF; Templeton DJ; Durier N; Matthews GV; Russell D; Law MG
Sex Health; 2017 Aug; 14(4):345-354. PubMed ID: 28482168
[TBL] [Abstract][Full Text] [Related]
32. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
[TBL] [Abstract][Full Text] [Related]
34. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
35. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
[TBL] [Abstract][Full Text] [Related]
36. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
[TBL] [Abstract][Full Text] [Related]
37. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.
Abdelaziz H; Omar H; Khalil M; Cordie A; Mohamed R; AbdAllah M; Abdel Maksoud MH; El Garhy N; Ali L; El Serafy M; Esmat G; Doss W
Expert Rev Anti Infect Ther; 2022 May; 20(5):789-795. PubMed ID: 34751609
[TBL] [Abstract][Full Text] [Related]
38. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.
Butt AA; Yan P; Aslam S; Sherman KE; Siraj D; Safdar N; Hameed B
Int J Infect Dis; 2020 Mar; 92():184-188. PubMed ID: 31978574
[TBL] [Abstract][Full Text] [Related]
40. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
